A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers

Advanced biliary tract cancers (ABTC) are among the deadliest malignancies with limited treatment options after progression on standard-of-care chemotherapy, which includes gemcitabine (GEM) and oxaliplatin (OX). The epidermal growth factor receptor inhibitor erlotinib has been explored in ABTC with...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Invest New Drugs
Hoofdauteurs: Goff, Laura W., Cardin, Dana B., Whisenant, Jennifer G., Du, Liping, Koyama, Tatsuki, Dahlman, Kimberly B., Salaria, Safia N., Young, Ruth T., Ciombor, Kristen K., Gilbert, Jill, Smith, Stephen James, Chan, Emily, Berlin, Jordan
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Springer US 2016
Onderwerpen:
Phase I Studies
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5306261/
https://ncbi.nlm.nih.gov/pubmed/27853997
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-016-0406-z
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items